These constructs were able to induce MUC1-specific, class-switched antibodies in the absence of a canonical adjuvant, and were capable of inducing complement-dependent lysis of MCF-7 breast cancer cells, while T cell responses to the vaccines were not reported. This evidence concerns the gene MUC1 and breast carcinoma.